These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23062821)

  • 1. Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization.
    Lecis D; Mastrangelo E; Belvisi L; Bolognesi M; Civera M; Cossu F; De Cesare M; Delia D; Drago C; Manenti G; Manzoni L; Milani M; Moroni E; Perego P; Potenza D; Rizzo V; Scavullo C; Scolastico C; Servida F; Vasile F; Seneci P
    Bioorg Med Chem; 2012 Nov; 20(22):6709-23. PubMed ID: 23062821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homo- and heterodimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part I: Synthesis.
    Manzoni L; Belvisi L; Bianchi A; Conti A; Drago C; de Matteo M; Ferrante L; Mastrangelo E; Perego P; Potenza D; Scolastico C; Servida F; Timpano G; Vasile F; Rizzo V; Seneci P
    Bioorg Med Chem; 2012 Nov; 20(22):6687-708. PubMed ID: 23036335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A NMR and computational study of Smac mimics targeting both the BIR2 and BIR3 domains in XIAP protein.
    Potenza D; Belvisi L; Vasile F; Moroni E; Cossu F; Seneci P
    Org Biomol Chem; 2012 Apr; 10(16):3278-87. PubMed ID: 22407164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.
    Zobel K; Wang L; Varfolomeev E; Franklin MC; Elliott LO; Wallweber HJ; Okawa DC; Flygare JA; Vucic D; Fairbrother WJ; Deshayes K
    ACS Chem Biol; 2006 Sep; 1(8):525-33. PubMed ID: 17168540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582).
    Hennessy EJ; Adam A; Aquila BM; Castriotta LM; Cook D; Hattersley M; Hird AW; Huntington C; Kamhi VM; Laing NM; Li D; MacIntyre T; Omer CA; Oza V; Patterson T; Repik G; Rooney MT; Saeh JC; Sha L; Vasbinder MM; Wang H; Whitston D
    J Med Chem; 2013 Dec; 56(24):9897-919. PubMed ID: 24320998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for bivalent Smac-mimetics recognition in the IAP protein family.
    Cossu F; Milani M; Mastrangelo E; Vachette P; Servida F; Lecis D; Canevari G; Delia D; Drago C; Rizzo V; Manzoni L; Seneci P; Scolastico C; Bolognesi M
    J Mol Biol; 2009 Sep; 392(3):630-44. PubMed ID: 19393243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design and molecular profiling of Smac-mimetics selective for cellular IAPs.
    Corti A; Milani M; Lecis D; Seneci P; de Rosa M; Mastrangelo E; Cossu F
    FEBS J; 2018 Sep; 285(17):3286-3298. PubMed ID: 30055105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains.
    Nikolovska-Coleska Z; Meagher JL; Jiang S; Kawamoto SA; Gao W; Yi H; Qin D; Roller PP; Stuckey JA; Wang S
    Anal Biochem; 2008 Mar; 374(1):87-98. PubMed ID: 18023397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells.
    Sun H; Lu J; Liu L; Yang CY; Wang S
    ACS Chem Biol; 2014 Apr; 9(4):994-1002. PubMed ID: 24521431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2.
    Cossu F; Mastrangelo E; Milani M; Sorrentino G; Lecis D; Delia D; Manzoni L; Seneci P; Scolastico C; Bolognesi M
    Biochem Biophys Res Commun; 2009 Jan; 378(2):162-7. PubMed ID: 18992220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the X-linked inhibitor of apoptosis protein through 4-substituted azabicyclo[5.3.0]alkane smac mimetics. Structure, activity, and recognition principles.
    Mastrangelo E; Cossu F; Milani M; Sorrentino G; Lecis D; Delia D; Manzoni L; Drago C; Seneci P; Scolastico C; Rizzo V; Bolognesi M
    J Mol Biol; 2008 Dec; 384(3):673-89. PubMed ID: 18851976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of small-molecule Smac mimetics as IAP antagonists.
    Wang S
    Curr Top Microbiol Immunol; 2011; 348():89-113. PubMed ID: 21072626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.
    Kester RF; Donnell AF; Lou Y; Remiszewski SW; Lombardo LJ; Chen S; Le NT; Lo J; Moliterni JA; Han X; Hogg JH; Liang W; Michoud C; Rupert KC; Mischke S; Le K; Weisel M; Janson CA; Lukacs CM; Fretland AJ; Hong K; Polonskaia A; Gao L; Li S; Solis DS; Aguilar D; Tardell C; Dvorozniak M; Tannu S; Lee EC; Schutt AD; Goggin B
    J Med Chem; 2013 Oct; 56(20):7788-803. PubMed ID: 24093940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theoretical studies on the interactions of XIAP-BIR3 domain with bicyclic and tricyclic core monovalent Smac mimetics.
    Ling B; Dong L; Zhang R; Wang Z; Liu Y; Liu C
    J Mol Graph Model; 2010 Nov; 29(3):354-62. PubMed ID: 20980180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzazepinones and benzoxazepinones as antagonists of inhibitor of apoptosis proteins (IAPs) selective for the second baculovirus IAP repeat (BIR2) domain.
    Donnell AF; Michoud C; Rupert KC; Han X; Aguilar D; Frank KB; Fretland AJ; Gao L; Goggin B; Hogg JH; Hong K; Janson CA; Kester RF; Kong N; Le K; Li S; Liang W; Lombardo LJ; Lou Y; Lukacs CM; Mischke S; Moliterni JA; Polonskaia A; Schutt AD; Solis DS; Specian A; Taylor RT; Weisel M; Remiszewski SW
    J Med Chem; 2013 Oct; 56(20):7772-87. PubMed ID: 24083782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smac mimetics as IAP antagonists.
    Fulda S
    Semin Cell Dev Biol; 2015 Mar; 39():132-8. PubMed ID: 25550219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design, synthesis and characterization of potent, drug-like monomeric Smac mimetics as pro-apoptotic anticancer agents.
    Bianchi A; Ugazzi M; Ferrante L; Lecis D; Scavullo C; Mastrangelo E; Seneci P
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2204-8. PubMed ID: 22342627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a heterodimeric Smac-based peptide that features sequences specific to both the BIR2 and BIR3 domains of the X-linked inhibitor of apoptosis protein.
    Speer KF; Cosimini CL; Splan KE
    Biopolymers; 2012; 98(2):122-30. PubMed ID: 22020922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents.
    Peng Y; Sun H; Lu J; Liu L; Cai Q; Shen R; Yang CY; Yi H; Wang S
    J Med Chem; 2012 Jan; 55(1):106-14. PubMed ID: 22148838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalent SMAC Mimetics for Treating Cancer by Antagonizing Inhibitor of Apoptosis Proteins.
    Zhu H; Li Y; Liu Y; Han B
    ChemMedChem; 2019 Dec; 14(23):1951-1962. PubMed ID: 31692274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.